NYSE:DCIMachinery
Will Donaldson’s (DCI) Q3 Beat and Life Sciences Outlook Change Its Core Investment Narrative?
Earlier this week, Donaldson Company reported fiscal 2026 third-quarter results with adjusted earnings and revenue exceeding analyst estimates and rising from a year ago, while guiding for full-year adjusted EPS of $3.94–$4.01 and organic sales growth of 3–5% across its segments.
A key takeaway for investors is the especially strong outlook for the higher-growth Life Sciences segment, where management is targeting 9–11% sales growth, potentially shifting the company’s overall business mix...